161 related articles for article (PubMed ID: 36333311)
1. High-potency PD-1/PD-L1 degradation induced by Peptide-PROTAC in human cancer cells.
Dai MY; Shi YY; Wang AJ; Liu XL; Liu M; Cai HB
Cell Death Dis; 2022 Nov; 13(11):924. PubMed ID: 36333311
[No Abstract] [Full Text] [Related]
2. A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells.
Shi YY; Dong DR; Fan G; Dai MY; Liu M
Front Immunol; 2023; 14():1237964. PubMed ID: 37849747
[TBL] [Abstract][Full Text] [Related]
3. Effect of the hairpin structure of peptide inhibitors on the blockade of PD-1/PD-L1 axis.
Wang K; Song Y; Su Y; Liang Y; Wang L
Biochem Biophys Res Commun; 2020 Jun; 527(2):453-457. PubMed ID: 32336542
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and evaluation of PD-L1 peptide antagonists as new anticancer agents for immunotherapy.
Orafaie A; Sadeghian H; Bahrami AR; Rafatpanah H; Matin MM
Bioorg Med Chem; 2021 Jan; 30():115951. PubMed ID: 33360579
[TBL] [Abstract][Full Text] [Related]
5. Discovery of Small-Molecule Inhibitors of the PD-1/PD-L1 Axis That Promote PD-L1 Internalization and Degradation.
Wang T; Cai S; Cheng Y; Zhang W; Wang M; Sun H; Guo B; Li Z; Xiao Y; Jiang S
J Med Chem; 2022 Mar; 65(5):3879-3893. PubMed ID: 35188766
[TBL] [Abstract][Full Text] [Related]
6. Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1.
Ishibashi M; Tamura H; Sunakawa M; Kondo-Onodera A; Okuyama N; Hamada Y; Moriya K; Choi I; Tamada K; Inokuchi K
Cancer Immunol Res; 2016 Sep; 4(9):779-88. PubMed ID: 27440711
[TBL] [Abstract][Full Text] [Related]
7. PD-1 and PD-L1 expression on the prognosis of ovarian cancer.
Li RP; Li YW; Guo YZ
J Biol Regul Homeost Agents; 2019; 33(4):1161-1166. PubMed ID: 31309818
[No Abstract] [Full Text] [Related]
8. Emerging Role of Ubiquitination in the Regulation of PD-1/PD-L1 in Cancer Immunotherapy.
Hu X; Wang J; Chu M; Liu Y; Wang ZW; Zhu X
Mol Ther; 2021 Mar; 29(3):908-919. PubMed ID: 33388422
[TBL] [Abstract][Full Text] [Related]
9. HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity.
Wang H; Yao H; Li C; Shi H; Lan J; Li Z; Zhang Y; Liang L; Fang JY; Xu J
Nat Chem Biol; 2019 Jan; 15(1):42-50. PubMed ID: 30397328
[TBL] [Abstract][Full Text] [Related]
10. Beyond T Cells: Understanding the Role of PD-1/PD-L1 in Tumor-Associated Macrophages.
Lu D; Ni Z; Liu X; Feng S; Dong X; Shi X; Zhai J; Mai S; Jiang J; Wang Z; Wu H; Cai K
J Immunol Res; 2019; 2019():1919082. PubMed ID: 31781673
[TBL] [Abstract][Full Text] [Related]
11. Structural Characterization of a Macrocyclic Peptide Modulator of the PD-1/PD-L1 Immune Checkpoint Axis.
Zyla E; Musielak B; Holak TA; Dubin G
Molecules; 2021 Aug; 26(16):. PubMed ID: 34443436
[TBL] [Abstract][Full Text] [Related]
12. Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy.
Liu H; Zhao Z; Zhang L; Li Y; Jain A; Barve A; Jin W; Liu Y; Fetse J; Cheng K
J Immunother Cancer; 2019 Oct; 7(1):270. PubMed ID: 31640814
[TBL] [Abstract][Full Text] [Related]
13. A PD-L1 and VEGFR2 dual targeted peptide and its combination with irradiation for cancer immunotherapy.
Jiao L; Dong Q; Zhai W; Zhao W; Shi P; Wu Y; Zhou X; Gao Y
Pharmacol Res; 2022 Aug; 182():106343. PubMed ID: 35798286
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy.
Tu X; Qin B; Zhang Y; Zhang C; Kahila M; Nowsheen S; Yin P; Yuan J; Pei H; Li H; Yu J; Song Z; Zhou Q; Zhao F; Liu J; Zhang C; Dong H; Mutter RW; Lou Z
Mol Cell; 2019 Jun; 74(6):1215-1226.e4. PubMed ID: 31053471
[TBL] [Abstract][Full Text] [Related]
15. In silico screening and surface plasma resonance-based verification of programmed death 1-targeted peptides.
Zhang P; Li C; Ji X; Gao M; Lyu S; Dai X; Du J
Chem Biol Drug Des; 2020 Mar; 95(3):332-342. PubMed ID: 31755641
[TBL] [Abstract][Full Text] [Related]
16. Regulation of programmed death-ligand 1 expression in response to DNA damage in cancer cells: Implications for precision medicine.
Sato H; Jeggo PA; Shibata A
Cancer Sci; 2019 Nov; 110(11):3415-3423. PubMed ID: 31513320
[TBL] [Abstract][Full Text] [Related]
17. Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation.
Pan C; Yang H; Lu Y; Hu S; Wu Y; He Q; Dong X
Eur J Med Chem; 2021 Mar; 213():113170. PubMed ID: 33454550
[TBL] [Abstract][Full Text] [Related]
18. Rational design and development of a peptide inhibitor for the PD-1/PD-L1 interaction.
Boohaker RJ; Sambandam V; Segura I; Miller J; Suto M; Xu B
Cancer Lett; 2018 Oct; 434():11-21. PubMed ID: 29920293
[TBL] [Abstract][Full Text] [Related]
19. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
[TBL] [Abstract][Full Text] [Related]
20. An inhibitor of programmed death ligand 1 enhances natural killer cell-mediated immunity against malignant melanoma cells.
Lee YS; Heo W; Choi HJ; Cho HR; Nam JH; Ki YG; Lee HR; Son WC; Park YS; Kang CD; Bae J
PLoS One; 2021; 16(4):e0248870. PubMed ID: 33793576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
